The Food and Drug Administration refused to accept an application seeking the approval of a drug to treat HIV from CytoDyn — a setback that could delay a decision for months, if not years.
The so-called Refuse-to-File letter, issued by the FDA against CytoDyn’s drug called leronlimab, is also the most damning evidence yet that CEO Nader Pourhassan and other company executives might be misleading investors.
About the Author Reprints
